Bringing back the mo’

Buysiders are crossing their fingers that the rally that began this quarter can get some legs under it. Hopeful signs include the sector’s divergence from the broader markets and high trading volumes. Given the sensitivity of the market to any news, they note the rally easily could be derailed - or sustained - by high-profile regulatory or clinical events.

Since the beginning of the quarter, biotech indices and fund inflows have been on fire: the NASDAQ’s NBI is up 12%, the AMEX BTK has gained 13% and the BioCentury 100 is up 10%...